Driving the development of your obesity drug assets efficiently is critical for success. Physiologically based pharmacokinetic (PBPK) modeling offers a powerful approach to streamline drug development and support ‘First-to-Invent’ innovators as you optimize lead compound selection, formulation assessment, and dosing strategies—all with fewer iterations.

Join Dr. Maxime Le Merdy, industry expert and Director of PBPK Research and Collaborations at Simulations Plus, as he explores how PBPK modeling can enhance drug efficacy and safety in obese populations while increasing the likelihood of acquisition or out-licensing of an appealing asset. In this webinar, you’ll gain insights into how other companies are leveraging modeling and simulation to make data-driven decisions that de-risk clinical development and increase chances for regulatory success.

Key Takeaways:

✅ Special considerations for the differences in drug absorption and systemic distribution in obese population groups
✅ How PBPK modeling accelerates obesity drug development with fewer iterations
✅ How modeling and simulation research enhances acquisition and out-licensing potential

Register now.